Cell-Free DNA Platform Positions Touchlight in Gene Therapy Supply Chain

A LinkedIn post from Touchlight highlights its cell-free DNA platform as an alternative to plasmid DNA, emphasizing rapid production, scalable manufacturing and deployment flexibility. The post also underscores the absence of bacterial impurities, positioning the company’s dbDNA technology as a potentially differentiated input for genetic medicines.

According to the post, the platform targets applications in gene therapies, mRNA vaccines and cell-based treatments, aiming to support programs from discovery through commercialisation. For investors, this focus suggests Touchlight is seeking to capture upstream value in the cell and gene therapy supply chain, which could enhance its strategic relevance if adoption by developers and manufacturers expands.